WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Thursday, March 26, 2015

Alzheimer’s Drug Shows Promise in Slowing Disease

FoxFeed Blog


Posted by  Maggie McGuire, March 23, 2015
On Friday morning our CEO sent around an email. Subject: This is big!
He was sharing news from pharmaceutical company Biogen Idec(renamed today as simply Biogen) around an Alzheimer’s drug in development with strong implications for Parkinson’s research. The drug — aducanumab (BIIB037) — showed safety and positive impact not only on clinical symptoms but also on brain imaging scans.
Alzheimer’s, like Parkinson’s, is a disease of protein clumps. In Alzheimer’s the protein amyloid-beta aggregates into what scientists call plaques. In Parkinson’s disease (PD), alpha-synuclein protein clumps to form Lewy bodies. Researchers believe these plaques and Lewy bodies harm brain cells.
Biogen compared BIIB037 to placebo in 166 people in the early stages of Alzheimer’s disease. Analysis showed no change in plaques among those given the placebo, but there was significant change in those who received the drug. In fact, those given more of the drug showed greater decrease in plaques and less decline in cognitive and functional abilities.
Big news, indeed. The company is planning a Phase III study with hopes to begin later this year.
What does this mean for people with Parkinson’s disease?
While not everyone with Parkinson’s develops dementia, some do. People with PD dementia often have amyloid plaques like those seen in Alzheimer’s, so a drug such as BIIB037 may benefit that population, though further testing would be necessary.
These findings are a win for Parkinson’s research, too, because BIIB037 is an antibody (disease fighters that help the body fend off harmful substances). Scientists are currently testing two antibody approaches against alpha-synuclein in clinical trials to slow Parkinson’s progression. The positive results from this Alzheimer’s study are a boost that this therapeutic strategy shows real promise.
This excitement comes with a caveat, though. Biogen has a biomarker tool to measure the impact of its drug; Alzheimer’s researchers can measure amyloid load in the brain through imaging capabilities. We don’t have such a tool for Parkinson’s research yet.
Our senior vice president of research programs Mark Frasier, PhD, is at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in France, where Biogen shared its study results.
“I was at the presentation, and it was definitely impressive — both the changes on the biomarker scan but also the slowing of clinical progression. My takeaway from this entire meeting is how much we need better biomarkers of Parkinson’s disease,” he wrote in an email.
The Michael J. Fox Foundation is working urgently to validate Parkinson’s biomarkers. We’ve assembled a team to develop the technology to image the alpha-synuclein protein in the brain. And the MJFF-led Parkinson’s Progression Markers Initiative study is working toward measures of alpha-synuclein in blood or spinal fluid. Research toward these vital research tools is a top priority for the Foundation.
Learn more about PPMI and how biomarkers would speed testing of antibodies and other therapeutic approaches to slow Parkinson’s disease.
https://www.michaeljfox.org/foundation/news-detail.php?alzheimer-drug-shows-promise-in-slowing-disease&utm_source=social&utm_medium=facebook&utm_content=researchnews&utm_campaign=alzheimers-drug&s_src=researchnews&s_subsrc=alzheimers-drug#prclt-rvl1LfK9

No comments:

Post a Comment